GeneReach Business Summary

GeneReach Biotechnology Corp. (4171.TWO) operates a vertically integrated molecular diagnostics business model, generating revenue through the sale of proprietary POCKIT™ insulated isothermal PCR (iiPCR) platforms and recurring sales of specialized reagent kits. The company’s operations are segmented into Animal Health (aquaculture, livestock, and companion animals), Human Health (point-of-care diagnostics), and Food Safety. By utilizing a "razor-and-blade" strategy, GeneReach captures high-margin value from decentralized testing markets, providing laboratory-grade results in field settings where traditional infrastructure is absent. In the competitive landscape, GeneReach contends with local peers such as PlexBio Co. and Taiwan Advanced Nanotech, as well as global diagnostic leaders like Seegene and IDEXX Laboratories. While larger competitors dominate centralized laboratory infrastructure, GeneReach maintains a niche leadership position by providing portable, cost-effective, and rapid diagnostic solutions specifically optimized for the global aquaculture and livestock industries. The company was founded by Dr. Chang-Kei (C.K.) Chang and is currently led by Chairman Zhengzhong (Leo) Liu and CEO De Yu (Simon) Zhong, who has directed the firm’s commercial strategy since August 2022. Chairman Liu, an expert in Animal Science from Oregon State University, provides the technical leadership essential for the company's core agricultural and veterinary segments. The executive team is further supported by Deputy General Manager Yuyan Fu, who oversees corporate support and strategic planning. GeneReach’s governance is characterized by significant insider and institutional backing, with major shareholders including Luveiton Ltd. and the Liu family. This leadership team is currently focused on leveraging the company’s portfolio of over 60 patents to expand its human In Vitro Diagnostic (IVD) offerings and automated extraction systems, positioning the firm as a key technological exporter within Taiwan’s biotechnology sector.